文献速递血液净化与透析

在两个欧洲队列中重新评估左心室质量指数对慢性肾衰竭的预后价值

Reappraisal in two European cohorts of the prognostic power of left ventricular mass index in chronic kidney failure.
PubMed 文献 · Kidney Int · 2016-12-20

研究在意大利南部CREED队列207例和法国Manhes医院队列287例血液透析患者中,分析左心室质量指数(LVMI)对全因和心血管死亡的预后价值。随访两年期间123例患者死亡(心血管死亡占65%)。Cox模型显示LVMI和ARO风险评分均与全因及心血管死亡显著相关,但LVMI的判别能力低于ARO风险评分(全因死亡低10%,心血管死亡低5%),且对基于ARO风险评分的模型校准改善有限,增加的非显著判别力(综合判别指数+2%和+3%)和重分类能力有限(净重分类指数+4.3%和+8.8)。

要点

  • 在血液透析患者中,LVMI和ARO风险评分均与全因及心血管死亡显著相关。
  • LVMI的判别能力低于ARO风险评分(全因死亡低10%,心血管死亡低5%)。
  • LVMI对基于ARO风险评分的模型增加的非显著判别力和重分类能力有限。

核心结论

  • 尽管左心室肥厚仍是终末期肾衰竭的基本治疗目标,但仅为了风险分层而测量LVMI是不合理的。

研究设计与样本

  • 分析两个欧洲队列:意大利南部CREED队列207例血液透析患者和法国Manhes医院队列287例患者,均测量了LVMI。
  • 随访两年,期间123例患者死亡(心血管死亡占65%)。

主要发现

  • Cox模型中,LVMI和ARO风险评分均与全因死亡和心血管死亡显著相关。
  • LVMI的判别能力(Harrell's C指数)低于ARO风险评分:全因死亡低10%,心血管死亡低5%。
  • LVMI对基于ARO风险评分的模型校准改善有限,增加的非显著判别力为综合判别指数+2%和+3%。
  • LVMI对ARO风险评分的重分类能力有限:净重分类指数+4.3%和+8.8。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Left ventricular hypertrophy is a strong causal risk factor of cardiovascular morbidity and death in end stage kidney failure, and its prognostic value is taken for granted in this population. However, the issue has never been formally tested by state-of-art prognostic analyses. Therefore, we determined the prognostic power of the left ventricular mass index (LVMI) for all-cause and cardiovascular death beyond and above that provided by well validated clinical risk scores, the annualized rate of occurrence cohort risk scores (ARO, all cause death risk and cardiovascular risk). Two large cohorts that measured LVMI in 207 hemodialysis patients in the South Italian CREED cohort and 287 patients in the French Hospital Manhes cohort were analyzed. Over a two year follow-up, 123 patients died (cardiovascular death 65%). In Cox models both the LVMI and the ARO risk scores were significantly related to all-cause and cardiovascular death. In prognostic analyses, LVMI per se showed an inferior discriminatory power (Harrell's C index) to that of the ARO risk scores (all-cause death: -10%; cardiovascular death: -5%). LVMI largely failed to improve model calibration based on the ARO risk scores, and added nonsignificant discriminatory power (Integrated Discrimination Index +2% and +3%) and quite limited reclassification ability (Net Reclassification Index +4.3%, and +8.8) to the ARO risk scores. Thus, while left ventricular hypertrophy remains a fundamental treatment target in end stage kidney failure, the measurement of LVMI solely for risk stratification is unwarranted in this condition.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Tripepi G, Pannier B, D'Arrigo G, et al. Reappraisal in two European cohorts of the prognostic power of left ventricular mass index in chronic kidney failure. Kidney Int. 2016. PMID: 28010886. doi:10.1016/j.kint.2016.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。